What we do

For almost 50 years we’ve been creating high-quality medicines and making them accessible to the people who need them.

Learn more about how we do this across North America, MENA and Europe.

Investors

Together we are building a leading generics and specialty pharmaceutical company where everyone can thrive.

Learn more about our strategy, investment case and track record of success.

Responsibility

Learn more about how we put better health within reach, every day and make a difference to people’s lives.

Careers

We're looking for people who share our passion and want to help us make a real difference in the world.

Newsroom

Featured

Press Release, Financial Results 06 November 2025

Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US Press Release, Product 08 December 2025 Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region Press Release, Business Development 19 November 2025 Hikma signs an exclusive agreement with DGI Group to bring Claritag® to the MENA region
Hikma confirms 2025 guidance and updates medium-term growth outlook Press Release, Financial Results 06 November 2025 Hikma confirms 2025 guidance and updates medium-term growth outlook
Hikma Pharmaceuticals announces the launch of STARJEMZA™ (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection Press Release, Product 06 November 2025 Hikma Pharmaceuticals announces the launch of STARJEMZA™ (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection